Abstract

Within the context of pharmacy technician's (PT) continuing training (CT), a theoretical instruction in onco-hematology has been developed for PT working in our cytotoxic preparation unit (CPU). The aim of this study is to describe the approach taken, tools used and present knowledge assessment (KA). A previous KA has been conducted using quiz available on GERPAC website which listing 36 drugs. Forty-five minutes sessions were conducted. KA was assessing before and after each session and 2 years after. PT appreciation was also evaluated. The previous KA served to targeting gaps and insisted on: indications, mechanism of action and cytotoxic drugs costs. Interactive sessions were led by a pharmacist and concerned about 17 diseases and 3 of the most prescribed cytotoxic drugs: 47 drugs summaries have been written by a pharmacist. The before-after knowledge improvement is significant (P>0.0005) (average [a] before=4.7 vs. a after=9.6). Two years after, this was non-significant but assessment results remain higher than before sessions (a=4.7 vs. 6.8). All PT wish sessions sustainability, 92% reported an adequate comprehension level. Lack of time and staff constitute a brake for sustaining and this was also highlighted by other units. Share this experience on a web platform could be interesting. Nevertheless, supports used during sessions should be suitable in conformity with the hospital practice and updated with new therapeutic.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.